Beta Drugs Board of Directors

Get the latest insights into the leadership at Beta Drugs. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Rahul Batra Chairperson & Managing Director
Mr. Varun Batra Joint Managing Director
Mrs. Seema Chopra Whole Time Director
Mr. Balwant Singh Whole Time Director
Mr. Manmohan Khanna Independent Director
Mr. Ashutosh Shukla Whole Time Director
Mr. Rohit Parti Independent Director

Beta Drugs Share price

BETA

1887

10.65 (0.57%)
NSE
BSE
Last updated on 4 Sep, 2025 | 14:59 IST
BUYSELL
Today's High

1910.00

Today's Low

1865.00

52 Week Low

1429.52

52 Week High

2215.24

The current prices are delayed, login to your account for live prices

Beta Drugs FAQs

The board at Beta Drugs consists of experienced professionals, including Mr. Rahul Batra , Mr. Varun Batra , and others, overseeing the company’s strategic and corporate governance.

Directors at Beta Drugs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Rahul Batra is the current chairman at Beta Drugs.

Executive directors at Beta Drugs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Beta Drugs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Beta Drugs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.